Carl Icahn didn't amass a net worth of an estimated $16.6 billion by making dumb moves. So when Dow Jones reported that the billionaire bought a stake in Bristol-Myers Squibb (NYSE: BMY), it captured the attention of the investment …
CHICAGO, Sept. 14, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BMY, CLF, HTZ, …
traders are definitely monitoring Bristol-Myers Squibb’s price action to see if this move attracts further buying into the stock. Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical company that develops, …
Fallout from Bristol-Myers Squibb Co.'s bombshell announcement that it was dramatically slashing first-quarter and full-year earnings and revenue expectations pushed the stock down nearly 15 percent Thursday, and analysts expressed …
an analyst at Jefferies who advises holding the stock, called the study "positive but unquantified data." Interim results from the late-stage study, known as CheckMate-227, were highly anticipated by Wall Street after earlier missteps set …
The third-quarter earnings season is off to a strong start. The results of the companies that have reported numbers show that earnings and revenue growth pace is accelerating from the first two quarters. In particular, revenue growth has …
Syngene International has expanded its ongoing drug discovery and development operations with its US-based partner Bristol-Myers Squibb till 2026, the company said in a notice to the stock exchanges. The expansion would also …
BMY is a stock I ... the opinions of Interactive Investor Trading Limited or its affiliates and has not been approved or issued by Interactive Investor Trading Limited. You should be aware that the other participants of the above discussion group …
Bristol-Myers Squibb stock closed up 5.42% Thursday after the drugmaker reported strong drug sales and raised guidance for the year. The biopharmaceutical company said global revenues for the third quarter were driven by sales of …